[PARP inhibitors in breast cancer: Current clinical development and perspectives]. / Inhibiteurs de PARP dans les cancers du sein : développement clinique actuel et perspectives.
Bull Cancer
; 107(10): 1024-1041, 2020 Oct.
Article
en Fr
| MEDLINE
| ID: mdl-33004179
ABSTRACT
The association of a germline mutation in the BRCA1/2 genes in breast cancer leads to a higher genomic instability and, thus, a potential higher sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. In this review, we will summarize the different DNA-repair pathways including PARP-dependent mechanisms that support the use of PARP inhibitors. We will present clinical trials evaluating PARP inhibitors alone or in combination in early or advanced stage breast cancer. We will then discuss the different mechanisms involved in the resistance to PARP inhibitors. We will also introduce the concept of BRCAness by which the use of PARP inhibitors could be extended to BRCA1/2-wild type patients. Finally, we will describe the new channels implemented for the theranostic genetic screening.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Inhibidores de Poli(ADP-Ribosa) Polimerasas
Tipo de estudio:
Prognostic_studies
Límite:
Female
/
Humans
Idioma:
Fr
Revista:
Bull Cancer
Año:
2020
Tipo del documento:
Article
País de afiliación:
Francia